ADIL Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ADIL shares is 13, representing 3.03% of the company's common stock.

BLACKROCK INC., in the last quarter, reduced its stake in ADIL by -13.94% restricting it's holding to 194.36 thousand shares of worth nearly $40.47K. SUSQUEHANNA INTERNATIONAL GROUP, LLP also lessened -18.89% of the ADIL shares from its portfolio, reducing its holding to 180.29 thousand shares of worth $37.50K. TWO SIGMA INVESTMENTS, LP also shunned ADIL shares holding by -0.47% last quarter which brought its holding to 17.62 thousand shares worth $3.67K.

As per its latest 13F filing, ADVISOR GROUP HOLDINGS, INC. increased its stake in ADIL by 3% in the last quarter. The institutional holder raised its holding to 24.05 thousand shares having worth more than $5.00K. CREATIVE PLANNING also added 100% more shares of ADIL to its portfolio, raising its holding to 10 thousand shares of worth $2.08K. RENAISSANCE TECHNOLOGIES LLC also increased its ADIL shares holding by 6.14% which brought its holding to 107.1 thousand shares worth $22.00K.

The insider with the most stakes in ADIL is Stilley William B. III , Chief Executive Officer at the company. Additionally, ADIL stock is highly held by Chief Medical Officer Johnson Bankole A. and director Gilliland Robertson H. among others.

Company executives, directors, and other insiders own 1.8% percent of Adial Pharmaceuticals, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which ADIL insiders have sold stock, totaling 0 shares. Insiders that have sold shares include JOHNSON BANKOLE A..

There have been 0 transaction(s) during the past 6-months in which Adial Pharmaceuticals, Inc. insiders have bought stock, totalling 0 shares

Around 0 Adial Pharmaceuticals, Inc. shares are held by insiders, which represents about 1.8% of ADIL stock.

ADIL Chief Executive Officer, Stilley William B. III holds the largest portfolio of the company's shares. ADIL shares owned by Stilley total nearly 937.65 thousand.

MANCHESTER CAPITAL MANAGEMENT LLC is the largest institutional owner in ADIL which holds 1.2 million shares worth $250.35K or 4.54% of the total ADIL shares outstanding followed by STATE STREET CORP with ownership of 52.35 thousand shares representing 0.2% of the ADIL ownership. TRUIST FINANCIAL CORP is the third largest stakeholder with 33.86 thousand shares or 0.13% of the ownership worth more than $7.05K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ADIL is concerned, it is a stock which is not optionable.

Number of ADIL shares short is 78.88K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 6.47M shares of ADIL are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ADIL has 6.29M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ADIL is 0.65.